244 related articles for article (PubMed ID: 25739426)
1. Heat shock protein 90 is required for ex vivo neutrophil-driven autoantibody-induced tissue damage in experimental epidermolysis bullosa acquisita.
Tukaj S; Hellberg L; Ueck C; Hänsel M; Samavedam U; Zillikens D; Ludwig RJ; Laskay T; Kasperkiewicz M
Exp Dermatol; 2015 Jun; 24(6):471-3. PubMed ID: 25739426
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid.
Shimanovich I; Mihai S; Oostingh GJ; Ilenchuk TT; Bröcker EB; Opdenakker G; Zillikens D; Sitaru C
J Pathol; 2004 Dec; 204(5):519-27. PubMed ID: 15538734
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human IgA1 and IgA2 autoantibodies to type VII collagen induce subepidermal blistering ex vivo.
Recke A; Trog LM; Pas HH; Vorobyev A; Abadpour A; Jonkman MF; van Zandbergen G; Kauderer C; Zillikens D; Vidarsson G; Ludwig RJ
J Immunol; 2014 Aug; 193(4):1600-8. PubMed ID: 25024393
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases.
Tukaj S; Zillikens D; Kasperkiewicz M
Exp Dermatol; 2015 Aug; 24(8):567-71. PubMed ID: 25980533
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses.
Tukaj S; Tiburzy B; Manz R; de Castro Marques A; Orosz A; Ludwig RJ; Zillikens D; Kasperkiewicz M
Exp Dermatol; 2014 Aug; 23(8):585-90. PubMed ID: 24961936
[TBL] [Abstract][Full Text] [Related]
6. GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa acquisita.
Samavedam UK; Iwata H; Müller S; Schulze FS; Recke A; Schmidt E; Zillikens D; Ludwig RJ
J Immunol; 2014 Jan; 192(2):559-71. PubMed ID: 24337383
[TBL] [Abstract][Full Text] [Related]
7. Topically Applied Hsp90 Blocker 17AAG Inhibits Autoantibody-Mediated Blister-Inducing Cutaneous Inflammation.
Tukaj S; Bieber K; Kleszczyński K; Witte M; Cames R; Kalies K; Zillikens D; Ludwig RJ; Fischer TW; Kasperkiewicz M
J Invest Dermatol; 2017 Feb; 137(2):341-349. PubMed ID: 27659253
[TBL] [Abstract][Full Text] [Related]
8. Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation.
Hellberg L; Samavedam UKSRL; Holdorf K; Hänsel M; Recke A; Beckmann T; Steinhorst K; Boehncke WH; Kirchner T; Möckel N; Solbach W; Zillikens D; Schmidt E; Ludwig RJ; Laskay T
J Invest Dermatol; 2013 Oct; 133(10):2390-2399. PubMed ID: 23448878
[TBL] [Abstract][Full Text] [Related]
9. The retinoid-related orphan receptor alpha is essential for the end-stage effector phase of experimental epidermolysis bullosa acquisita.
Sadeghi H; Gupta Y; Möller S; Samavedam UK; Behnen M; Kasprick A; Bieber K; Müller S; Kalies K; de Castro Marques A; Recke A; Schmidt E; Zillikens D; Laskay T; Mariani J; Ibrahim SM; Ludwig RJ
J Pathol; 2015 Sep; 237(1):111-22. PubMed ID: 25953430
[TBL] [Abstract][Full Text] [Related]
10. Epidermolysis bullosa acquisita: what's new?
Ishii N; Hamada T; Dainichi T; Karashima T; Nakama T; Yasumoto S; Zillikens D; Hashimoto T
J Dermatol; 2010 Mar; 37(3):220-30. PubMed ID: 20507385
[TBL] [Abstract][Full Text] [Related]
11. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage.
Chiriac MT; Roesler J; Sindrilaru A; Scharffetter-Kochanek K; Zillikens D; Sitaru C
J Pathol; 2007 May; 212(1):56-65. PubMed ID: 17380558
[TBL] [Abstract][Full Text] [Related]
12. Induction of experimental epidermolysis bullosa acquisita by immunization with murine collagen VII.
Sesarman A; Sitaru C
Methods Mol Biol; 2013; 961():371-87. PubMed ID: 23325658
[TBL] [Abstract][Full Text] [Related]
13. Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets.
Kasperkiewicz M; Müller R; Manz R; Magens M; Hammers CM; Somlai C; Westermann J; Schmidt E; Zillikens D; Ludwig RJ; Orosz A
Blood; 2011 Jun; 117(23):6135-42. PubMed ID: 21490339
[TBL] [Abstract][Full Text] [Related]
14. Experimental models of epidermolysis bullosa acquisita.
Sitaru C
Exp Dermatol; 2007 Jun; 16(6):520-31. PubMed ID: 17518993
[TBL] [Abstract][Full Text] [Related]
15. T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita.
Bieber K; Witte M; Sun S; Hundt JE; Kalies K; Dräger S; Kasprick A; Twelkmeyer T; Manz RA; König P; Köhl J; Zillikens D; Ludwig RJ
Sci Rep; 2016 Dec; 6():38357. PubMed ID: 27917914
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease.
Hashimoto T; Ishii N; Ohata C; Furumura M
J Pathol; 2012 Sep; 228(1):1-7. PubMed ID: 22692770
[TBL] [Abstract][Full Text] [Related]
17. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients.
Woodley DT; Ram R; Doostan A; Bandyopadhyay P; Huang Y; Remington J; Hou Y; Keene DR; Liu Z; Chen M
J Invest Dermatol; 2006 Jun; 126(6):1323-30. PubMed ID: 16543893
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin.
Sitaru C; Kromminga A; Hashimoto T; Bröcker EB; Zillikens D
Am J Pathol; 2002 Jul; 161(1):301-11. PubMed ID: 12107115
[TBL] [Abstract][Full Text] [Related]
19. Fcγ Receptor IIB Controls Skin Inflammation in an Active Model of Epidermolysis Bullosa Acquisita.
Kovacs B; Tillmann J; Freund LC; Nimmerjahn F; Sadik CD; Bieber K; Ludwig RJ; Karsten CM; Köhl J
Front Immunol; 2019; 10():3012. PubMed ID: 31993051
[TBL] [Abstract][Full Text] [Related]
20. Anti-type VII collagen autoantibodies, detected by enzyme-linked immunosorbent assay, fluctuate in parallel with clinical severity in patients with epidermolysis bullosa acquisita.
Ito Y; Kasai H; Yoshida T; Saleh MA; Amagai M; Yamagami J
J Dermatol; 2013 Nov; 40(11):864-8. PubMed ID: 24127822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
